Per the terms of the license, Ocugen is allowed to sell the jab in the U.S.
Food and Drug Administration for permission to start its phase 3 clinical trials, which it expects would conclude in the first half of next year.
Though both countries already have several other approved vaccines made by companies like Pfizer and Moderna, it’s possible that Ocugen could still have a shot at grabbing some of the market.
That doesn’t make it any more effective, but it does offer an alternative that may be appealing to some vaccine-hesitant people.
But Ocugen doesn’t have a license to sell its product worldwide, meaning that the WHO’s stamp of approval doesn’t really open the door to any opportunities for new revenue.
In other words, in the U.S., it’s the FDA that has the final say, and in Canada, it’s the Ministry of Health.
In my view, that means the future payoff of those programs is so uncertain that they shouldn’t be considered as heavily weighted arguments in favor of buying the stock.
or Canada, and then successfully steal some market share from powerful competitors in markets where majorities of the population are already fully vaccinated.
Because Ocugen has never made any revenue or gotten any of its medicines approved for sale, making inroads to holding even a small slice of the market will produce awesome year-over-year revenue growth.
I wouldn’t buy shares of this stock, as I don’t think that the company has any competitive advantages that will allow it to succeed in the long run, and I don’t find the prospect of a small biotech competing against established and powerful companies to be very appealing.